Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Steele

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Blood|June 23, 2022
Phagocytosing with TP53 and extracellular vesiclesAndrew J Steele
Blood|December 6, 2014
PI3K in CLL: are 2 isoforms better than 1?Andrew J Steele
Blood|July 14, 2018
Roring ahead with DOCK2Andrew J Steele
Leukemia Research Reports|October 27, 2015
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemiaMatthew D Blunt, Andrew J Steele
Blood|June 25, 2016
To BH3 profile or not to BH3 profileMatthew D Blunt, Andrew J Steele
Blood|December 31, 2016
Releasing the brakes on BTK-targeting miRNAMatthew D Blunt, Andrew J Steele
British Journal of Haematology|April 20, 2011
Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targetsR Gitendra Wickremasinghe, Archibald G Prentice, Andrew J Steele
Exploration of Targeted Anti-Tumor Therapy|September 14, 2020
Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitorsRachael Arthur, Beatriz Valle-Argos, Andrew J Steele, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 24, 2018
Ex-Vivo Signal Transduction Studies in Chronic Lymphocytic LeukemiaKarly-Rai Rogers-Broadway, Laura I Karydis, Rachel C Dobson, et al.
Blood|August 6, 2011
B-cell receptor signaling in chronic lymphocytic leukemiaFreda K Stevenson, Sergey Krysov, Andrew J Davies, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Blood|June 23, 2022
Phagocytosing with TP53 and extracellular vesiclesAndrew J Steele
Blood|December 6, 2014
PI3K in CLL: are 2 isoforms better than 1?Andrew J Steele
Blood|July 14, 2018
Roring ahead with DOCK2Andrew J Steele
Leukemia Research Reports|October 27, 2015
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemiaMatthew D Blunt, Andrew J Steele
Blood|June 25, 2016
To BH3 profile or not to BH3 profileMatthew D Blunt, Andrew J Steele
Blood|December 31, 2016
Releasing the brakes on BTK-targeting miRNAMatthew D Blunt, Andrew J Steele
British Journal of Haematology|April 20, 2011
Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targetsR Gitendra Wickremasinghe, Archibald G Prentice, Andrew J Steele
Exploration of Targeted Anti-Tumor Therapy|September 14, 2020
Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitorsRachael Arthur, Beatriz Valle-Argos, Andrew J Steele, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 24, 2018
Ex-Vivo Signal Transduction Studies in Chronic Lymphocytic LeukemiaKarly-Rai Rogers-Broadway, Laura I Karydis, Rachel C Dobson, et al.
Blood|August 6, 2011
B-cell receptor signaling in chronic lymphocytic leukemiaFreda K Stevenson, Sergey Krysov, Andrew J Davies, et al.
Pageof 7